CST, 60194SF, PD-1 (Pembrolizumab Biosimilar) Human Monoclonal Antibody

Monoclonal Antibody for studying PDCD1. Validated for Neutralizing. Highly specific and rigorously validated in-house, PD-1 (Pembrolizumab Biosimilar) Human Monoclonal Antibody (CST #60194) is ready to ship. Product Usage Information This product is intended for research use only (RUO). Optimal dilutions/concentrations should be determined by the end user. Formulation Supplied in 1X PBS, BSA and Azide Free Storage Store at -20°C. This product will freeze at -20°C so it is recommended to aliquot into single-use vials to avoid multiple freeze/thaw cycles . A slight precipitate may be present and can be dissolved by gently vortexing. This will not interfere with antibody performance. Specificity / Sensitivity PD-1 (Pembrolizumab Biosimilar) Human Monoclonal Antibody was confirmed to bind to its intended target protein PD-1 using flow cytometry. Species Reactivity: Human Source / Purification PD-1 (Pembrolizumab Biosimilar) Human mAb is produced at Cell Signaling Technology. Pembrolizumab is an antibody that is directed against the extracellular region of human PD-1. Background The programmed cell death 1 protein (PD-1, PDCD1, CD279) is a member of the CD28 family of immunoreceptors that regulate T cell activation and immune responses (1-3). The PD-1 protein contains an extracellular Ig V domain, a transmembrane domain, and a cytoplasmic tail that includes an immunoreceptor tyrosine-based inhibitory motif (ITIM) and an immunoreceptor tyrosine-based switch motif (ITSM). PD-1 is activated by the cell surface ligands PD-L1 and PD-L2 (4). Upon activation, PD-1 ITIM and ITSM phosphorylation leads to the recruitment of the protein tyrosine phosphatases SHP-1 and SHP-2, which suppress TCR signaling (5-7). In addition to activated T cells, PD-1 is expressed in activated B cells and monocytes, although its function in these cell types has not been fully characterized (8). The PD-1 pathway plays an important role in immune tolerance (3); however, research studies show that cancer cells often adopt this pathway to escape immune surveillance (9). Consequently, blockade of PD-1 and its ligands is proving to be a sound strategy for neoplastic intervention (10). Alternate Names CD279; hPD-1; hPD-l; hSLE1; PD-1; PD1; PDCD1; programmed cell death 1; programmed cell death 1 protein; Programmed cell death protein 1; Protein PD-1; SLEB2; systemic lupus erythematosus susceptibility 2 Specification REACTIVITY: H SENSITIVITY: Endogenous Source/Isotype: Human IgG4 kappa